Pre-Conference Day
Monday, June 10

Investment & Business Development Focus Day

With current market headwinds, it is essential that cell therapy leaders are able to juggle limited cash runways and identify which programs to prioritize, all while maintaining efficient speed-to-clinic and market for safe and effective therapies.

Beyond Oncology Bootcamp Day

With exciting clinical results demonstrated in lupus, MS and many other autoimmune conditions, the cell therapy community are looking beyond treating purely cancer indications more than ever.

Understanding the State of Play for Allogeneic BioPharma Investment

10:00 am Forecasting the Landscape for Allogeneic Cell Therapies Over the Next Few Years to Help Guide Business Decisions

10:30 am Demystifying Key Investment Criteria for the Allogeneic Cell Therapy Space

11:00 am Morning Break & Networking

Building Capital & Support to take Your Biotech Company to the Next Level

11:30 am Exploring Partnership Models to Optimize Investment in Allogeneic Cell Therapies

12:00 pm Turning Your Unique Concept into a Successful Biotech Start-Up

12:30 pm Lunch Break

1:30 pm Panel: Meet the Investors – Your Questions Answered

  • Sahil Chopra Vice President - Investment, Vertex Ventures HC
  • Noelle Hutchins Senior Investment Associate, Omega Funds
  • Sean Evans Investor, Johnson & Johnson New!
  • Gregory Fiore Board Member, Eterna Therapeutics
  • Patrick Rivers Head of Research, Aquilo Capital Management, Co-Chair, Business Models & Investments Subcommittee, Aquilo Capital Management LLC

2:30 pm Close of Pre-Conference Day

Tackling Autoimmune Conditions with Scalable & Effective Therapies

10:00 am Unlocking the Potential of Allogeneic Cell Therapies for Inflammatory Disease

  • Omid Veiseh Associate Professor, CPRIT Scholar in Cancer Research, Rice University

10:30 am Combatting Infectious Disease with Allogeneic Invariant NK Cell Therapies

11:00 am Morning Break & Networking

Reviewing Clinical Trial Strategies & Lessons Learned to Streamline Your Transition to the Clinic

11:30 am Applications for Allogeneic Cell Therapies for Rare & Orphan Diseases

  • Lauren Bor Process Development Manager, TCBiopharm New!

12:00 pm Considerations for Developing Allogeneic Therapies in Non-Cancer Settings

  • Wonjong Si Associate Director - Cell Therapy Platform Process, Bayer

12:30 pm Lunch Break

1:30 pm Panel: The Future of Allogeneic Cell Therapies in Autoimmune Indications & Beyond

  • Marc van Dijk Chief Scientific Officer, MiNK Therapeutics New!
  • Samik Basu VP, Translational Research, Cabaletta Bio New!

2:30 pm Close of Pre-Conference Day